| Name | Title | Contact Details |
|---|
AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.
Parker Medical Inc is a Bridgewater, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CommonHealth comprises Altum, Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn, EvoLogue, Ferguson, HLS, MBS/Vox, ProCom, Qi, Solara and Valos.
MEDI USA is a Whitsett, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.